Intellia Therapeutics, Inc.
NTLA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$519,021 | -$481,192 | -$474,186 | -$267,892 |
| Dep. & Amort. | $10,285 | $8,976 | $7,572 | $6,891 |
| Deferred Tax | $0 | $0 | $0 | $8,929 |
| Stock-Based Comp. | $154,273 | $134,050 | $91,400 | $47,009 |
| Change in WC | $11,878 | -$52,452 | -$53,873 | -$22,904 |
| Other Non-Cash | -$6,295 | -$3,468 | $95,800 | $2,937 |
| Operating Cash Flow | -$348,880 | -$394,086 | -$333,287 | -$225,030 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$5,778 | -$13,985 | -$58,390 | -$12,756 |
| Net Acquisitions | $0 | $0 | -$44,682 | -$3,000 |
| Inv. Purchases | -$935,573 | -$904,464 | -$429,032 | -$1,020,620 |
| Inv. Sales/Matur. | $1,066,918 | $887,102 | $647,581 | $485,598 |
| Other Inv. Act. | $0 | $0 | $44,832 | $0 |
| Investing Cash Flow | $125,567 | -$31,347 | $160,309 | -$550,778 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $0 | $0 | $0 | $0 |
| Stock Issued | $176,899 | $119,795 | $565,789 | $693,570 |
| Stock Repurch. | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | $8,848 | $10,528 | $17,166 | $43,118 |
| Financing Cash Flow | $185,747 | $130,323 | $582,955 | $736,688 |
| Forex Effect | $0 | $0 | $0 | $0 |
| Net Chg. in Cash | -$37,566 | -$295,110 | $409,977 | -$39,120 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $240,353 | $535,463 | $125,486 | $164,606 |
| End Cash | $202,787 | $240,353 | $535,463 | $125,486 |
| Free Cash Flow | -$354,658 | -$408,071 | -$391,677 | -$237,786 |